A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

This study tests a three-drug combination — venetoclax, isatuximab, and dexamethasone — in patients with multiple myeloma (a blood cancer) that has come back or stopped responding to previous treatments. This combination targets cancer cells in multiple ways to overcome drug resistance. **You may be eligible if:** - You have a confirmed diagnosis of multiple myeloma - Your cancer has relapsed (come back) or is refractory (stopped responding) to prior treatment - You have received at least one prior line of therapy - You have adequate organ function - You are in generally acceptable health **You may NOT be eligible if:** - You have never been treated for myeloma - You have active, uncontrolled infections - You have certain heart, liver, or kidney problems - You are pregnant or breastfeeding - You have had prior treatment with venetoclax Talk to your doctor to see if this trial is right for you.